3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
5
Carcinoma, Non-Small-Cell Lung
4
Skin Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Zollinger-Ellison Syndrome
1
Waldenstrom Macroglobulinemia
1
Vipoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Mycosis Fungoides
1
Interventions
HhAntag691
25
Imiquimod
12
Biopsy
12
sonidegib
11
Aminolevulinic Acid
9
cemiplimab
8
Photochemotherapy
8
Nivolumab
8
methyl 5-aminolevulinate
7
Mohs Surgery
7
1-phenyl-3,3-dimethyltriazene
7
Tomography, Optical Coherence
6
Surgical Procedures, Operative
6
Specimen Handling
5
Radiotherapy
5
Itraconazole
5
pembrolizumab
4
daromun
4
Microscopy, Confocal
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Curettage
4
Standard of Care
3
Niacinamide
3
IPI-926
3
CTLA-4 Antigen
3
3-ingenyl angelate
3
tazarotene
2
talimogene laherparepvec
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Capecitabine
×
Dermatologic
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled